Medicinal composition and application thereof

A technology of composition and medicine, which is applied in the field of pharmaceutical composition and its application, and can solve problems such as unsatisfactory therapeutic effect

Active Publication Date: 2010-11-10
JIANGSU KANION PHARMA CO LTD +1
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Prostatic hyperplasia is a group of diseases with multiple etiologies and requires long-term medication. If synthetic drugs such as α1-receptor blockers and 5α-reductase inhibitors that only target a specific target point have certain side effects during long-term use, such as Hypotension, impotence, sexual dysfunction, headache, etc., and the treatment effect is not satisfactory, thus limiting the application of these drugs in the treatment of benign prostatic hyperplasia

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition and application thereof
  • Medicinal composition and application thereof
  • Medicinal composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1～31

[0113] The linolenic acid, palmitic acid, N-(2-hydroxyethyl), 9,12,15-octadecatrienamide, glycerol linolenic acid, 15 , 16-dihydroxylinoleic acid, ethyl linolenic acid, glyceryl palmitate, 24-methylenecholesteryl palmitate, 1,3-dipalmitic acid-2-linolenic acid triglyceride, 1,3- Dilinolenic acid-2-palmitate triglyceride, 24-methylenecholesteryl linoleate, cycloene eucalyptyl linoleate, pollen sterol linoleate, 1,3-dipalmitic acid diglyceride, 1-Palmito-2-heptadecanoic acid diglyceride, kaempferol, quercetin, isorhamnetin, gossythin, kaempferol 7-O-(6'-rhamnosyl) glucoside, N 1 , N 5 , N 10 -Tris-(E)-coumaroyl amidine, N 1 , N 5 , N 10-Tris-(Z)-coumaroyl amidine, 1-O-(β-D-glucose)-(2S,3S,4R)-2N-[(2'R)-2'-hydroxytetradecanoyl The pharmaceutical composition of the present invention is obtained by mixing enoic acid]-octadecene-3,4-diol, putrescine and indole-3-acetic acid according to the components and contents described in Table 1.

[0114] Among them, the preparation of...

Embodiment 29

[0192] Test sample: Example 29: The proportion of plant extracts of fatty acid compounds 45%, flavonoids plant extracts 35% and alkaloids plant extracts 20% by mass percentage, combined with fatty acids, flavonoids Compounds and alkaloids, namely the anti-prostatic hyperplasia pharmaceutical composition of the present invention (wherein the active ingredients are about mass percentage: 40% of fatty acid compounds, 30% of flavonoids and 10% of alkaloids) .

[0193] Positive control:

[0194] Qianliekang (Pulean Tablets), the maximum clinical dosage of 60 kg adults is 12 tablets / d.

[0195] Determination of rat dose: According to the conversion relationship between the effective doses of humans and animals, the rat dose is calculated as 6 times the clinical dose of 60 kg adults, that is, 1.2 tablets / kg. Preparation method: Take 36 Qianliekang tablets, use distilled water as a solvent, add Tween-80 as a co-solvent, and prepare a suspension of 300ml.

[0196] Chenetone (General...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicinal composition, which comprises two or three of a, b and c, wherein a is long-chain fatty acid compounds of a formula I or plant extract containing the same; b is flavonoid compounds of a formula II or plant extract containing the same; and c is the following alkaloid compounds or plant extract containing the same: N1,N5,N10-tri-(E / Z)-coumaroyl spermidine, 1-O-(beta-D-glucose)-(2S, 3S, 4R)-2N-[(2'R)-2'-hydroxytetracosenoicacid]-octadecylene-3,4-diol, putrescine and indol-3-acetic acid. The medicinal composition of the invention can be used for preparing aromatizing enzyme inhibitor, 5alpha reductase inhibitor, alpha1-adrenergic receptor antagonist, cyclooxygenase-2 inhibitor, prostate-specific antigen (PSA) secretion inhibitor, anti-inflammation medicamentor medicament for resisting prostatic hyperplasia, prostatitis or prostatic cancer.

Description

technical field [0001] The invention belongs to the field of pharmaceutical compositions, in particular to a pharmaceutical composition and its application. Background technique [0002] Benign prostatic hyperplasia (BPH) is a common physiological disease in elderly men. When the disease causes a series of symptoms such as urinary obstruction, it is called benign prostatic hyperplasia. The autopsy reports of 1075 cases abroad show that: at the age of 25 to 30, 10% of men can see early benign prostatic hyperplasia lesions under the microscope; with the increase of age, the incidence of histologically diagnosed prostatic hyperplasia also increases accordingly; To 51 to 60 years old, the incidence rate increased to 75%; to 85 years old, about 90% of men had histological benign prostatic hyperplasia lesions. It can be seen from the above that with the acceleration of the aging of the population in my country, the incidence of benign prostatic hyperplasia caused by aging continu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/202A61K31/232A61K31/20A61K31/201A61K31/164A61K31/7032A61K31/405A61K31/23A61K31/575A61K31/132A61K31/165A61P43/00A61P29/00A61P13/08A61P35/00
Inventor 杨义芳李坤杨必成金丽丽
Owner JIANGSU KANION PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap